Vitamin D with asthma and COPD: not a false hope? A systematic review and meta-analysis

Zhang, L L; Gong, J.G.; Liu, C T

doi:10.4238/2014.february.13.10

Cited by 17 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In COPD patients, a weak relationship was observed between serum vitamin D and FEV1/FVC 36 . This is more likely due to less sample size 37 . Vitamin D has an anti-inflammatory effect that can be modified by exposure to cigarette smoke 38 .…”

Section: Discussionmentioning

confidence: 99%

Serum vitamin D is associated with improved lung function markers but not with prevalence of asthma, emphysema, and chronic bronchitis

Ganji

Al-Obahi

Yusuf

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Hypovitaminosis D has been linked to several non-bone diseases. Relation between 25-hydroxyvitamin D [25(OH)D] and lung function and lung diseases has received little attention at the global level. Cross-sectional data from three National Health and Nutrition Examination Surveys, 2007-2008, 2009-2010, and 2011-2012 were used to investigate the relationship between serum 25(OH)D concentrations and lung function makers [forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and lung diseases (asthma, emphysema, and chronic bronchitis) with multivariate regression models (n = 11,983; men, 6,010; women, 5,973). Serum 25(OH)D concentrations were directly associated with FVC and FEV1 (P for trend < 0.01). Individuals in the 4th quartile serum 25(OH)D had significantly higher FVC and FEV1 compared to those in the 1st quartile (P < 0.01). When data were stratified based on gender and smoking status, we found similar associations between serum 25(OH)D concentrations and lung function markers. There was no relation between serum 25(OH)D and prevalence of asthma, chronic bronchitis, and emphysema in US adults. Serum 25(OH)D concentration is associated with improved lung function markers but not with the prevalence of asthma, emphysema, and chronic bronchitis. controlled studies are needed to determine if the vitamin D supplementation improves lung function in adults and in smokers. Abbreviations 25(OH)D 25-Hydroxyvitamin D BMI Body mass index FVC Forced vital capacity FEV1 Forced expiratory volume in 1 s LC-TMS Liquid chromatography-tandem mass spectrometry NCHS National Center for Health Statistics NHANES National Health and Nutrition Examination Survey OR Odds ratio PIR Poverty income ratio Vitamin D, a lipophilic nutrient, is obtained from diet and supplements. It can also be synthesized in the skin from 7-dehydrocholesterol when exposed to Sun's UV-B light. 25-dihydroxyvitamin D [25(OH)D] is the major circulatory form and a commonly used biomarker of vitamin D status 1 although its use is questioned in studies linking 25(OH)D concentration with health outcomes 2. The classical function of vitamin D is to maintain the calcium homeostasis. Recent evidence points a role for vitamin D in non-bone infirmities such as type-2 diabetes 3 , metabolic syndrome 4,5 , obesity 6 , cardiovascular diseases 7 , some cancers 8,9 , depression 10,11 , and infectious disease 12. Vitamin D deficiency is a global health problem 13. In the US, the vitamin D deficiency [< 50 nmol/L of 25(OH)

show abstract

Section: Discussionmentioning

confidence: 99%

Serum vitamin D is associated with improved lung function markers but not with prevalence of asthma, emphysema, and chronic bronchitis

Ganji

Al-Obahi

Yusuf

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Previously, two meta-analyses were conducted to assess the association between vitamin D and COPD. Zhang et al15 just included two studies, and no statistical significance was found in the analysis. Zhu et al16 conducted a meta-analysis of 18 studies.…”

Section: Discussionmentioning

confidence: 99%

“…However, the conclusion was not definite. Two meta-analyses on the roles of vitamin D in COPD have been conducted 15,16. However, the studies did not include enough articles, did not extract correct data, pooled the levels of vitamin D from serum and plasma, included participants with vitamin D supplement, or did not analyze the sources of high heterogeneity.…”

Section: Introductionmentioning

confidence: 99%

The association between vitamin D and COPD risk, severity, and exacerbation: an updated systematic review and meta-analysis

Zhu

Wang

et al. 2016

COPD

107

View full text Add to dashboard Cite

BackgroundIn recent years, the pleiotropic roles of vitamin D have been highlighted in various diseases. However, the association between serum vitamin D and COPD is not well studied. This updated systematic review and meta-analysis aimed to assess the relationship between vitamin D and the risk, severity, and exacerbation of COPD.MethodsA systematic literature search was conducted in PubMed, Medline, EMBASE, Chinese National Knowledge Infrastructure, Wanfang, and Weipu databases. The pooled risk estimates were standardized mean difference (SMD) with 95% confidence interval (CI) for vitamin D levels and odds ratio (OR) with 95% CI for vitamin D deficiency. Meta-regression and subgroup analyses were performed on latitude, body mass index, and assay method.ResultsA total of 21 studies, including 4,818 COPD patients and 7,175 controls, were included. Meta-analysis showed that lower serum vitamin D levels were found in COPD patients than in controls (SMD: −0.69, 95% CI: −1.00, −0.38, P<0.001), especially in severe COPD (SMD: −0.87, 95% CI: −1.51, −0.22, P=0.001) and COPD exacerbation (SMD: −0.43, 95% CI: −0.70, −0.15, P=0.002). Vitamin D deficiency was associated with increased risk of COPD (OR: 1.77, 95% CI: 1.18, 2.64, P=0.006) and with COPD severity (OR: 2.83, 95% CI: 2.00, 4.00, P<0.001) but not with COPD exacerbation (OR: 1.17, 95% CI: 0.86, 1.59, P=0.326). Assay methods had significant influence on the heterogeneity of vitamin D deficiency and COPD risk.ConclusionSerum vitamin D levels were inversely associated with COPD risk, severity, and exacerbation. Vitamin D deficiency is associated with increased risk of COPD and severe COPD but not with COPD exacerbation. It is worth considering assay methods in the heterogeneity sources analysis of association between vitamin D deficiency and COPD.

show abstract

“… 4 , 5 There are several risk factors associated with COPD in later life, such as smoking, diabetes, and vitamin D deficiency. 6 – 8 Since COPD is associated with increased early mortality compared with general population, development of new treatments aiming to prolong their lives is important. In addition, identification of clinical characteristics predicting mortality is also helpful to improve the efficacy of current treatments for an individual patient.…”

Section: Introductionmentioning

confidence: 99%

Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease

Zhang¹,

Liu²,

Liang³

et al. 2015

COPD

View full text Add to dashboard Cite

Patients with chronic obstructive pulmonary disease (COPD) are often at high risk of early death. Identification of prognostic biomarkers for COPD may aid in improving their survival by providing early strengthened therapy for high-risk patients. In the present study, we investigated the prognostic role of hyperuricemia at baseline on the prognosis of patients with COPD. Thirty-four patients with COPD with hyperuricemia were matched (1:2) to 68 patients with COPD without hyperuricemia and of similar age and sex. Data from those patients with COPD were evaluated retrospectively. The role of hyperuricemia on mortality was first analyzed using the Kaplan–Meier method, and multivariate Cox regression model was then used to evaluate the prognostic significance of hyperuricemia in patients with COPD. Hyperuricemia was not associated with other baseline characteristics in patients with COPD. Kaplan–Meier survival curve showed that patients with COPD with hyperuricemia had higher risk of mortality compared with patients with normouricemia, and the P-value for log-rank test was 0.005. In univariate analysis, hyperuricemia was associated with higher risk of mortality in patients with COPD (hazard ratio =2.29, 95% CI =1.07–4.88, P=0.032). In the multivariate analysis, hyperuricemia was independently associated with higher risk of mortality in patients with COPD (hazard ratio =2.68, 95% CI =1.18–6.09, P=0.019). In conclusion, hyperuricemia is a promising biomarker of early mortality in patients with COPD.

show abstract

Vitamin D with asthma and COPD: not a false hope? A systematic review and meta-analysis

Cited by 17 publications

References 37 publications

Serum vitamin D is associated with improved lung function markers but not with prevalence of asthma, emphysema, and chronic bronchitis

Serum vitamin D is associated with improved lung function markers but not with prevalence of asthma, emphysema, and chronic bronchitis

The association between vitamin D and COPD risk, severity, and exacerbation: an updated systematic review and meta-analysis

Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About